Business
Summit Therapeutics Appoints Dr. Maky Zanganeh as Co-CEO & President
Bob Duggan Remains Chairman of the Board of Directors and CEO Menlo Park, California, July 26, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:
About this update from Summit Therapeutics Inc.
[{"type":"text","content":"Bob Duggan Remains Chairman of the Board of Directors and CEO\nMenlo Park, California, July 26, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) announces that Dr. Maky Zanganeh, DDS, MBA, has been appointed as Co-Chief Executive Officer & President, effective immediately. Dr. Zanganeh was formerly the Company’s Chief Operating Officer, having served in that capacity since she joined the Company as an employee in November 2020, and remains a member of the Company’s Board of Directors. “Maky defines what it means to be a great leader,” said Robert W. Duggan, Executive Chairman and Chief Executive Officer of Summit. “We have assembled a world-class leadership team here at Summit and have guided a group of accomplished executives into the next chapter of our growth. As we seek to expand our pipeline through business development activities, as well as chart the path forward with our current pipeline drug candidates, there is no one, exemplified by Maky’s past successes, that is better prepared to lead us through this journey. I am proud to serve alongside Maky and partner with her expertise as the co-leaders of this organization built with the purpose of improving the condition of overall human health.” Prior to joining Summit, Dr. Zanganeh founded Maky Zanganeh and Associates in 2015, and from 2008 to 2015, she held multiple leadership positions at Pharmacyclics, Inc., culminating in her role as Chief Operating Officer. As COO of Pharmacyclics, she oversaw all clinical development, regulatory, research, and commercial functions in addition to all business-related matters. Dr. Zanganeh played a key role in the over $1 billion collaboration and license deal for ibrutinib with Janssen Biotech, Inc. in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. for $21 billion in 2015. She is currently a board member for Pulse Biosciences, Inc. Dr. Zanganeh received her DDS from the Louis Pasteur University (France) and her MBA from Schiller International University (France). Earlier this year, Dr. Zanganeh was an honored speaker at the United Nations’ 7th Anniversary of the February 11 Global Movement celebrating women and girls in science. Dr. Zanganeh was also named a “Top 10 Most Influential COOs of 2021” by Industry Era magazine. She earned the Fierce Biotech “Top Women in Biotech 2013” award and was a finalist f...